Can monoclonal antibodies duplicate the success with Ebola in COVID-19? Monoclonal antibodies could hold promise in COVID-19 treatment and prevention if the results bear out in clinical trials for efficacy, the nation’s leading infectious diseases expert told MedPage Today. “There’s a lot of activity and it’s a highly concentrated, highly specific, direct antiviral approach to a number of diseases. The success in Ebola was very encouraging,” said National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony Fauci, MD.
Several large U.S. states including Texas are not heeding new federal health officials’ calls to reduce COVID-19 testing of some exposed to the virus, joining a broad rebuke of the Trump administration by public health leaders.
The man recovered from that initial diagnosis but once he was back from Hong Kong, he once again tested positive for COVID-19 but was asymptomatic.
Is it safe to take public transit? It’s one of those tricky COVID-19 things to navigate … no pun intended.
The COVID-19 pandemic has taken a disproportionate toll on people with intellectual and developmental disabilities (IDDs), write the directors of the Intellectual and Developmental Disabilities Research Centers (IDDRC) Network, a nationwide group funded by NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development. The article was written by John Constantino, M.D., director of the IDDRC at Washington University School of Medicine in St. Louis, along with fellow IDDRC directors and leaders of the Association of University Centers on Disabilities. It appears in the American Journal of Psychiatry.
It’s hard to predict what may happen when California’s primary schools reopen. But when it comes to the state’s youngest students, data are more robust — and more reassuring. Scientists are reporting several cases of Covid-19 reinfection — but the implications are complicated
Texas and Louisiana were already struggling to contain the spread of the coronavirus when Hurricane Laura hit early Thursday, and now some experts are warning mass evacuations could be responsible for a new wave of infections.
A study of a gateway receptor for SARS-CoV-2 led by Walter Lukiw, PhD, Professor of Neuroscience, Neurology and Ophthalmology at LSU Health New Orleans’ Neuroscience Center of Excellence and School of Medicine, may help explain the wide variety of symptoms and organs involved with SARS-CoV-2 infection and COVID-19. The results suggest that a multi-organ infection with SARS-CoV-2 may be via the angiotensin-converting enzyme 2 (ACE2) receptor, which is found almost everywhere throughout the body. [Related Study in Cellular and Molecular Neurobiology]
In a preprint article posted to Research Square, investigators reported evidence that mild coronavirus disease 2019 (COVID-19) elicits a functional and persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immune response.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has rapidly spread throughout the world since December 2019 to become a global public health emergency for the elevated deaths and hospitalizations in Intensive Care Units. The severity spectrum of SARS-CoV-2 pneumonia ranges from mild to severe clinical conditions. The clinical course of SARS-CoV-2 disease is correlated with multiple factors including host characteristics (genetics, immune status, age and general health), viral load and, above all, the host distribution of the airways and lungs of the viral receptor cells. In this review, we will briefly summarize the current knowledge on the characteristics and management of COVID-19-pneumonia. However, other studies are needed to better understand the pathogenetic mechanisms induced by SARS-Cov-2 infection, and to evaluate the long-term consequences of the virus on the lungs. This article is protected by copyright. All rights reserved.
To characterise the clinical features of children and young people admitted to hospital with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the UK and explore factors associated with admission to critical care, mortality, and development of multisystem inflammatory syndrome in children and adolescents temporarily related to coronavirus disease 2019 (covid-19) (MIS-C).
Official Reporting for August 28, 2020
World Health Organization
(last updated 8/24)
Cumulative Cases: 23,057,288
Cumulative Deaths: 800,906
Confirmed Cases: 24,473,843
Confirmed Cases: 24,637,544
Total deaths: 180,165
Arizona: University Of Arizona Prevented Coronavirus Outbreak On Campus By Testing Wastewater – Huff Post
California: With days to go, August is already California’s deadliest month from COVID-19 – Mercury News
Hong Kong’s Free Virus Tests for All Is an Experiment in Trust – Bloomberg
Science and Tech
The primary goal of a COVID-19 vaccine is to keep people from getting very sick and dying. But there’s another goal — to prevent the spread of the disease — and it’s not clear most vaccine candidates currently under development can do that.
After Covid-19’s emergence in Buenos Aires led to a strict lockdown in March, Juliana Cassataro and her fellow vaccine researchers grew concerned. The U.S., Europe and China had already revved up their quests to obtain shots; how far back in line would Argentina have to wait for supplies?
SARS-CoV-2 Infectivity and Neurological Targets in the Brain – Cellular and Molecular Neurobiology
Sex-derived attributes contributing to SARS-CoV-2 mortality – Journal of Physiology
Symptomatic and Asymptomatic Viral Shedding in Pediatric Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Under the Surface – JAMA
Coping in Quarantine
After a very quiet spring, Julie Danziger, the managing partner of travel advisory Embark Beyond, spent the greater part of June and July booking compelling domestic alternatives for her clients, who normally favor Italian villas and Greek resorts at the end of summer. But something strange happened in August: No one was ready to go home.